Impact of 13-Valent Pneumococcal Conjugate Vaccine Used in Children on Invasive Pneumococcal Disease in Children and Adults in the United States : Analysis of Multisite , Population-based Surveillance

Matthew R. Moore, MD1, Ruth Link-Gelles, MPH1, William Schaffner, MD2 [Professor], Ruth Lynfield, MD3, Catherine Lexau, PhD3, Nancy M. Bennett, MD4 [Professor], Susan Petit, MPH5, Shelley M. Zansky, PhD6, Lee H. Harrison, MD7 [Professor], Arthur Reingold, MD8 [Professor], Lisa Miller, MD9, Karen Scherzinger, MS10, Ann Thomas, MD11, Monica M. Farley, MD12 [Professor], Elizabeth R. Zell, MStat1,13, Thomas H. Taylor Jr., MS1, Tracy Pondo, MS1, Loren Rodgers, PhD1, Lesley McGee, PhD1, Bernard Beall, PhD1, James H. Jorgensen, PhD14 [Professor], and Cynthia G. Whitney, MD1 1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

[1]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[2]  Á. Gentile.  [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination]. , 2014, Archivos argentinos de pediatria.

[3]  Robert J. Taylor,et al.  Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. , 2014, The Lancet. Respiratory medicine.

[4]  A. Steens,et al.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. , 2013, Vaccine.

[5]  D. Greenberg,et al.  Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Cherian,et al.  Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites , 2013, PLoS medicine.

[7]  S. Kaplan,et al.  Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine , 2013, The Pediatric infectious disease journal.

[8]  E. Bingen,et al.  Impact of 13-valent Pneumococcal Conjugate Vaccine on Pneumococcal Nasopharyngeal Carriage in Children With Acute Otitis Media , 2012, The Pediatric infectious disease journal.

[9]  W. Schaffner,et al.  Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. , 2012, The Journal of infectious diseases.

[10]  N. Andrews,et al.  Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. , 2011, The Lancet. Infectious diseases.

[11]  T. Lieu,et al.  Healthcare utilization and cost of pneumococcal disease in the United States. , 2011, Vaccine.

[12]  J. Verhaegen,et al.  Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. , 2011, Vaccine.

[13]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[14]  J. Treanor,et al.  Differential effects of pneumococcal vaccines against serotypes 6A and 6C. , 2008, The Journal of infectious diseases.

[15]  K. Poehling,et al.  National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States , 2006, Pediatrics.